Skip to main content
An official website of the United States government
Email

Biography

Dr. Alida Palmisano is a Bioinformatics Engineer in the Computational and Systems Biology Branch of the Biometric Research Program (BRP/DCTD). Dr. Palmisano supports the development and maintenance of software applications for BRP and works on analysis and visualization for projects involving high dimensional genomic data generated by various groups collaborating with BRP.  

Dr. Palmisano joined NCI/DCTD as a Postdoctoral fellow in 2014, and holds a GDIT contractor position since 2020. Before joining NCI, Dr. Palmisano was a postdoctoral fellow in Virginia Tech within the Departments of Computer Science and Biological Sciences developing software to support research about mathematical and computational models of cell cycle.

Currently, Dr. Palmisano uses her extensive expertise in programming and database management to maintain a web-application in support of the NCI Patient-Derived Models Repository (PDMR). Dr. Palmisano research interests in computational and systems biology cover a variety of topics including developing software with intuitive interfaces for researchers with no programming background, data management and analysis for cancer research clinical trials and more, as evident from Dr. Palmisano's publication record below.

Selected Publications

  1. Evrard YA, Alcoser SY, Mullendore M, Chen L, Lih C-J, Kannan VR, Datta V, Dutko L, Jiwani S, Rubinstein LV, Zhao Y, Williams PM, Palmisano A, Kuhlmann L, Simpson M, Kummar S, Das B, Karlovich C, Polley E, Li M-C, Chen AP, Hollingshead MG and Doroshow JH (2025) Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft models. Frontiers Oncolology 2025 May 19. 15:1571635. doi: 10.3389/fonc.2025.1571635. PMID: 40458731 PMCID: PMC12127203
  2. Konaté MM, Krushkal J, Li MC, Chen L, Kotliarov Y, Palmisano A, Pauly R, Xie Q, Williams PM, McShane LM, Zhao Y. Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts. J Transl Med. 2024 Aug 5;22(1):733. doi: 10.1186/s12967-024-05528-6. PubMed PMID: 39103840; PubMed Central PMCID: PMC11301937.
  3. Zhang P, Palmisano A, Kumar R, Li MC, Doroshow JH, Zhao Y. TPWshiny: an interactive R/Shiny app to explore cell line transcriptional responses to anti-cancer drugs. Bioinformatics. 2022 Jan 3;38(2):570-572. doi: 10.1093/bioinformatics/btab619. PubMed PMID: 34450618; PubMed Central PMCID: PMC10060698.
  4. Krushkal J, Negi S, Yee LM, Evans JR, Grkovic T, Palmisano A, Fang J, Sankaran H, McShane LM, Zhao Y, O'Keefe BR. Molecular genomic features associated with in vitro response of the NCI-60 cancer cell line panel to natural products. Mol Oncol. 2021 Feb;15(2):381-406. doi: 10.1002/1878-0261.12849. Epub 2020 Nov 24. PubMed PMID: 33169510; PubMed Central PMCID: PMC7858122.
  5. Chen AP, Kummar S, Moore N, Rubinstein LV, Zhao Y, Williams PM, Palmisano A, Sims D, O'Sullivan Coyne G, Rosenberger CL, Simpson M, Raghav KPS, Meric-Bernstam F, Leong S, Waqar S, Foster JC, Konaté MM, Das B, Karlovich C, Lih CJ, Polley E, Simon R, Li MC, Piekarz R, Doroshow JH. Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial. JCO Precis Oncol. 2021;5. doi: 10.1200/PO.20.00372. eCollection 2021. PubMed PMID: 33928209; PubMed Central PMCID: PMC8078898.

For the complete publications record, see Google Scholar full list of publications or ORCID full list of publications.
 

Email